Clear cell renal cell carcinoma (ccRCC) is one of the most common and aggressive malignancies of the urinary system. Despite being the first-line treatment for advanced ccRCC, vascular endothelial growth factor receptor inhibitors (VEGFRis) face significant limitations due to both initial and acquired resistance, which impede complete tumor eradication. Using a CRISPR/Cas9 library screening approach, MAP2K2 was identified as a resistance-associated gene for three prevalent VEGFRis (Sunitinib, Axitinib, and Sorafenib). A strong positive correlation was observed between MAP2K2 expression and resistance to these VEGFRis. Drug-resistant cell lines established through dose-escalation consistently exhibited elevated MAP2K2 expression and activation of the MEK/ERK signaling pathway. Notably, combining MEK inhibitors (MEKis) with VEGFRis significantly enhanced the sensitivity of these resistant cells, leading to pronounced cell death. Additionally, a positive feedback regulatory mechanism was discovered between SP1 and MAP2K2, wherein SP1 and MAP2K2 could enhance mutual expression, thereby maintaining MEK/ERK pathway activation. This study reveals that MEKis can effectively re-sensitize VEGFRi-resistant cells, offering a promising therapeutic strategy for overcoming VEGFRi resistance in ccRCC.
Keywords: Clear cell renal cell carcinoma; Drug resistance; MAP2K2; Vascular endothelial growth factor receptor inhibitors.
© The author(s).